Sanofi

News

Dupixent is first FDA-approved drug for rare skin disease

The long list of therapeutic uses for Sanofi and Regeneron's Dupixent has been lengthened by an FDA approval for rare skin disease bullous pemphigoid.

News

Beyfortus now has a direct rival after FDA OK for Enflonsia

MSD could soon enter the US market for drugs used to protect infants from RSV infections, setting up a rivalry with AstraZeneca/Sanofi's Beyfortus.

News

Sanofi starts shipping RSV drug early as rival nears market

As an FDA decision nears from a rival MSD drug, Sanofi is speeding up the rollout of RSV antibody Beyfortus to get ahead of this year's season.

News

ASCO 25: Sanofi hopes on-body delivery will boost Sarclisa

Can a new on-body injector version of Sanofi's Sarclisa help it claim market share from J&J's rival top-selling Darzalex in multiple myeloma?

News

Sanofi draws up $9.1bn plan to buy Blueprint Meds

Sanofi has bolstered its rare disease business with an agreement to buy Blueprint Medicines and blockbuster-in-waiting Ayvakit for ASM.

News

Sanofi admits giving free Olympics tickets to patients

Despite a voluntary admission of a breach of the ABPI code, Sanofi is deemed to have "brought discredit" on the pharma industry.

Dupixent is first FDA-approved drug for rare skin disease

Beyfortus now has a direct rival after FDA OK for Enflonsia

Sanofi starts shipping RSV drug early as rival nears market

ASCO 25: Sanofi hopes on-body delivery will boost Sarclisa

Sanofi draws up $9.1bn plan to buy Blueprint Meds

Sanofi admits giving free Olympics tickets to patients

Novo sues Lilly over 'misleading' GLP-1 ad campaigning

Discover a new era of healthcare panel engagement: Grounded ...

Sanofi

Editor's Picks